- Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Kanzaki H, Hoshida Y
- KMID: 2563481
- Clin Mol Hepatol.
- 2025 Jan;31(1):e121-e122.
- doi: 10.3350/cmh.2024.0886
-
- CITED
-
- Close
- SHARE
-
- Close
- Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
-
Kanzaki H, Hoshida Y
- KMID: 2563437
- Clin Mol Hepatol.
- 2025 Jan;31(1):308-310.
- doi: 10.3350/cmh.2024.0726
-
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C virus-induced hepatocellular carcinoma
-
Goossens N, Hoshida Y
- KMID: 2164359
- Clin Mol Hepatol.
- 2015 Jun;21(2):105-114.
- doi: 10.3350/cmh.2015.21.2.105
Hepatitis C virus (HCV) is a leading etiology of hepatocellular carcinoma (HCC). The interaction of HCV with its human host is complex and multilayered; stemming in part from the fact... -
- CITED
-
- Close
- SHARE
-
- Close
- In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment
-
Hirschfield H, Bian CB, Higashi T, Nakagawa S, Zeleke TZ, Nair VD, Fuchs BC, Hoshida Y
- KMID: 2438349
- Exp Mol Med.
- 2018 Jan;50(1):e419.
- doi: 10.1038/emm.2017.164
Tractable experimental model that accounts for inter-tumor molecular heterogeneity is a key element of anti-cancer drug development. Hepatocellular carcinoma is known to exhibit highly heterogeneous molecular aberrations across the tumors,... -
- CITED
-
- Close
- SHARE
-
- Close
- Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases
-
Bansal R, Nakagawa S, Yazdani S, van Baarlen J, Venkatesh , Koh AP, Song WM, Goossens N, Watanabe H, Beasley MB, Powell CA, Storm G, Kaminski N, van Goor H, Friedman S, Hoshida Y, Prakash J
- KMID: 2396801
- Exp Mol Med.
- 2017 Nov;49(11):e396.
- doi: 10.1038/emm.2017.213
Tissue fibrosis, characterized by excessive accumulation of aberrant extracellular matrix (ECM) produced by myofibroblasts, is a growing cause of mortality worldwide. Understanding the factors that induce myofibroblastic differentiation is paramount... -
- CITED
-
- Close
- SHARE
-
- Close
